Atea Pharma Q3 net loss widens to $33.1M; cash at $595.1M; pipeline milestones on track

Atea Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.16

Net loss of $33.1M ($0.40/share) vs $8.1M ($0.10) a year ago, driven by R&D spending surge to $28.2M.
Cash, cash equivalents and marketable securities $595.1M at Sept 30, down $13M from June 30.
Phase 3 SUNRISE-3 for bemnifosbuvir in COVID-19 enrollment ongoing; first interim analysis expected Q1 2024.
Phase 2 HCV combination trial (bemnifosbuvir + ruzasvir) lead-in cohort fully enrolled; initial data also due Q1 2024.
Interest income rose to $7.9M from $4.4M on higher yields; total operating expenses $40.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Atea Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2023

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-273532

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.